for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca-Oxford COVID-19 vaccine 79% effective in U.S. trial

FRANKFURT, March 22 (Reuters) - The COVID-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in a large U.S. trial at preventing symptomatic illness, and was 100% effective against severe or critical disease and hospitalisation.

Reporting by Ludwig Burger in Frankfurt and Pushkala Aripaka in Bengaluru; Editing by Josephine Mason, Mark Potter and Sherry Jacob-Phillips

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up